Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, Baselga J; Spanish Oncology Genitourinary Group. Bellmunt J, et al. Among authors: albanell j. Cancer. 2002 Aug 15;95(4):751-7. doi: 10.1002/cncr.10762. Cancer. 2002. PMID: 12209718 Free article. Clinical Trial.
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B. Domingo-Domenech J, et al. Among authors: albanell j. Clin Cancer Res. 2006 Sep 15;12(18):5578-86. doi: 10.1158/1078-0432.CCR-05-2767. Clin Cancer Res. 2006. PMID: 17000695 Clinical Trial.
Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.
Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascón P, Rojo F, Perona R, Rovira A, Albanell J. Tapia MA, et al. Among authors: albanell j. Cell Cycle. 2007 Sep 15;6(18):2284-92. doi: 10.4161/cc.6.18.4721. Epub 2007 Jul 10. Cell Cycle. 2007. PMID: 17890907 Free article.
Genetic changes in small cell lung carcinoma.
Arriola E, Cañadas I, Arumí M, Rojo F, Rovira A, Albanell J. Arriola E, et al. Among authors: albanell j. Clin Transl Oncol. 2008 Apr;10(4):189-97. doi: 10.1007/s12094-008-0181-1. Clin Transl Oncol. 2008. PMID: 18411191 Review.
Targeted therapies in breast cancer.
Rojo F, Albanell J, Rovira A, Corominas JM, Manzarbeitia F. Rojo F, et al. Among authors: albanell j. Semin Diagn Pathol. 2008 Nov;25(4):245-61. doi: 10.1053/j.semdp.2008.08.001. Semin Diagn Pathol. 2008. PMID: 19013891 Review.
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J. Rojo F, et al. Among authors: albanell j. Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417026
261 results